The NGS approach allows an in-depth clinical and molecular analysis of TP53 mutations, as demonstrated by the study of Grob et al. [14], which included a huge number (2200) of AML/MDS with an excess of blast (AML/MDS-EB). Here, TP53 is linked to acute myeloid leukemia.